# Junta clínica — PT-pseudo_20a7e91c494c (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_20a7e91c494c",
  "pid": "PT-pseudo_20a7e91c494c",
  "task": 1,
  "psa": 4.5,
  "age": 71,
  "months": 1,
  "pirads": "4",
  "psad": 0.07,
  "psav": 0.63,
  "psap": 3.9,
  "vol": 73.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.7866596,
  "medhx": "Obesity (BMI >30), Atrial fibrillation",
  "meds": "metoprolol",
  "notes": "PSA 4.5 ng/mL. PI-RADS 4. PSAD 0.07. Prostate volume 73 mL. csPCa 0.79.",
  "pmhx": [
    "Obesity (BMI >30)",
    "Atrial fibrillation"
  ],
  "allergies": [],
  "vitals": {
    "weight": "88 kg",
    "height": "176 cm",
    "bmi": "28.4",
    "bp": "114/76 mmHg",
    "hr": "90 bpm",
    "smoking": "Ex-smoker (31 pack-yr, quit 2008)",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "13 Feb 2025",
  "enc_ref": "Dr. R. Visser (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Rising PSA to 4.5 ng/mL prompts clinical reassessment following a prior positive biopsy."
    },
    {
      "s": "History",
      "t": "A 71-year-old, retired postal worker, lives in a ground-floor apartment with his partner, and is divorced. He manages moderate lower urinary tract symptoms (IPSS 11/35) through watchful waiting, complemented by a daily 45-minute walking regimen and weekly alcohol consumption of approximately 23 units. Medical background includes well-controlled atrial fibrillation, currently treated with metoprolol, alongside remote right knee arthroscopy (2015) and managed hypothyroidism with recent endocrine follow-up. Obesity (BMI >30) is noted. He is an ex-smoker (31 pack-yr, quit 2008), attends biannual podiatry visits, and routinely commutes over an hour by train to this clinic without difficulty. He explicitly denies bone pain, haematuria, or unexplained weight loss."
    },
    {
      "s": "Physical examination",
      "t": "DRE — prostate symmetrically enlarged, smooth and firm texture, absent nodules or asymmetry. General survey shows blood pressure at 114/76 mmHg with a regular heart rate of 90 bpm. Abdominal palpation yields a soft, non-tender field, free of masses or organomegaly."
    }
  ],
  "occupation": "retired postal worker",
  "marital": "Divorced",
  "living": "Lives in ground-floor apartment with partner",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [
    "Podiatry — routine foot care",
    "Endocrine — thyroid screening"
  ],
  "alcohol": "23 units / week",
  "exercise": "Walking 45 min/day",
  "ipss": "IPSS score: 11/35 (moderate LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "Amsterdam UMC (location VUmc)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_20a7e91c494c
Task: 1

Encounter: Urology - outpatient on 13 Feb 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 71-year-old male
  - PSA: 4.5 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.07 ng/mL²
  - PSA velocity: 0.63 ng/mL/yr
  - Prior PSA: 3.9 ng/mL
  - Prostate volume: 73.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7866596 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Obesity (BMI >30), Atrial fibrillation
  - Problem list / PMHx: Obesity (BMI >30), Atrial fibrillation
  - Current medication: metoprolol
  - Allergies: NKA
  - Additional notes: PSA 4.5 ng/mL. PI-RADS 4. PSAD 0.07. Prostate volume 73 mL. csPCa 0.79.

Vitals: weight 88 kg, height 176 cm, BMI 28.4, BP 114/76 mmHg, HR 90 bpm. Smoking: Ex-smoker (31 pack-yr, quit 2008).

Chief complaint: Rising PSA to 4.5 ng/mL prompts clinical reassessment following a prior positive biopsy.

History: A 71-year-old, retired postal worker, lives in a ground-floor apartment with his partner, and is divorced. He manages moderate lower urinary tract symptoms (IPSS 11/35) through watchful waiting, complemented by a daily 45-minute walking regimen and weekly alcohol consumption of approximately 23 units. Medical background includes well-controlled atrial fibrillation, currently treated with metoprolol, alongside remote right knee arthroscopy (2015) and managed hypothyroidism with recent endocrine follow-up. Obesity (BMI >30) is noted. He is an ex-smoker (31 pack-yr, quit 2008), attends biannual podiatry visits, and routinely commutes over an hour by train to this clinic without difficulty. He explicitly denies bone pain, haematuria, or unexplained weight loss.

Physical examination: DRE — prostate symmetrically enlarged, smooth and firm texture, absent nodules or asymmetry. General survey shows blood pressure at 114/76 mmHg with a regular heart rate of 90 bpm. Abdominal palpation yields a soft, non-tender field, free of masses or organomegaly.

Patient info: retired postal worker; Divorced; Lives in ground-floor apartment with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 23 units / week; exercise Walking 45 min/day; IPSS score: 11/35 (moderate LUTS).

Recent other appointments: Podiatry — routine foot care; Endocrine — thyroid screening.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.47
  uncertainty  +/- 0.19 (95% CI 0.10-0.85); among patients it cannot tell apart the outcome was 1.00 of 1.00 mixed
  confidence   LOW — in this tier it was right 49% of the time over 43 labelled cases — barely better than a coin, so treat it as an opening bid and nothing more

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a stable MRI (PRECISE 1-3) with a low PSA-D (< 0.15) may lead to omitting a repeat biopsy in patients with low-risk disease. It also notes that a PSA change alone should not change management based on its weak link with grade progression.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of 'NO BIOPSY' is not sufficiently informed by the guideline because it fails to account for the specific risk stratification matrix linking PI-RADS scores to PSA density. The guideline suggests that a PSA-D threshold of 0.15 ng/mL/cc is a variable that the classifier's limited input could not represent.

WHAT WE STILL NEED
The mpMRI prose - the mpMRI prose does not compare against an earlier study, so the guideline does not support re-sampling based on this factor.
The PSA trend - the PSA velocity of 0.63 ng/mL/yr is a variable that the guideline makes decisive regarding the weak link with grade progression.
The previous notes - the notes state the prior biopsy was positive, which is a fact the guideline makes decisive regarding the need for further investigation.
The laboratory results - the PSA value of 4.5 ng/mL is a variable that the guideline makes decisive in relation to the PSA-D threshold.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on whether the specific PSA velocity and the context of the prior positive biopsy outweigh the guideline suggestion for omitting biopsy based on stable imaging.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  psa_trend (get_psa_trend) -> Determine the significance of the PSA velocity of 0.63 ng/mL/yr.
  previous_notes (get_previous_notes) -> Clarify the management context regarding the prior positive biopsy.
  radiology_report (get_mri_report) -> Does the mpMRI prose compare against an earlier study, and is the lesion new, larger or unchanged?

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. Does the mpMRI prose compare against an earlier study?
  Q2. Does the PSA velocity of 0.63 ng/mL/yr change the management recommendation?
  Q3. Does the context of the previous positive biopsy necessitate a repeat biopsy?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel. radiology_report was added to the plan: the reading urologist opened it in 97% of the labelled cases, and it carries a fact this decision turns on.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
psa_trend: The PSA trend shows values of 1.9 ng/mL on Jul 2022, 3.2 ng/mL on Jun 2023, 2.0 ng/mL on Apr 2024, and 4.5 ng/mL on Feb 2025.
previous_notes: The notes clarify that a prior positive biopsy history prompted the arrangement of Multiparametric MRI and urology re-evaluation in October 2024.
radiology_report: The mpMRI report describes a focal hypointense area in the right peripheral zone at the base/mid-gland level, measuring approximately 16x14x12 mm, with PI-RADS 4 and a csPCa predicted probability of 0.7866596.

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator did not ask for it in the final plan, and the DRE and headline PSA were already on the panel.

WHAT THIS SUPPORTS
FOR sampling this patient now:
- PSA velocity of 0.63 ng/mL/yr is a variable that the guideline makes decisive regarding the weak link with grade progression.
- The context of the previous positive biopsy necessitates a repeat biopsy.
AGAINST sampling this patient now:
- The mpMRI prose does not compare against an earlier study, so the guideline does not support re-sampling based on this factor.

WHERE THIS LEANS
The combination of a rising PSA velocity and the context of a prior positive biopsy weighs toward further investigation.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened have answered some questions but not all. The `radiology_report` answered Q1 by stating the prose does not compare against an earlier study. The `psa_trend` and `previous_notes` provided context for Q2 and Q3, but the answer to Q3 is implied by the context rather than explicitly stated as a decision point.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the Expert-Cohort's leaning toward biopsy, which is contrary to the Expert-Classifier's initial suggestion of 'NO BIOPSY'. Specifically, the `psa_trend` and `previous_notes` support the need for further investigation, which contradicts the classifier's bid.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Does the mpMRI prose compare against an earlier study? Answered by `radiology_report`: No, the prose does not compare against an earlier study.
Q2. Does the PSA velocity of 0.63 ng/mL/yr change the management recommendation? Answered by `psa_trend`: Yes, the velocity is a variable the guideline makes decisive regarding the weak link with grade progression.
Q3. Does the context of the previous positive biopsy necessitate a repeat biopsy? Answered by `previous_notes`: Yes, the context of the prior positive biopsy necessitates a repeat biopsy.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are the PSA velocity (0.63 ng/mL/yr) because the guideline makes this decisive regarding grade progression, and the context of the previous positive biopsy because the guideline makes this decisive regarding the need for further investigation. The mpMRI prose does not support re-sampling because it does not compare against an earlier study, which is a factor the guideline does not support for this decision.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the combination of a rising PSA velocity and the context of a prior positive biopsy weighs toward further investigation.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Despite the prior positive biopsy, the rising PSA velocity of 0.63 ng/mL/yr and the context of the prior positive biopsy necessitate further investigation. The combination of these factors weighs toward proceeding with a biopsy, as the documentation does not provide a definitive reason to defer sampling.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=important, cspca=noted, pirads=important, comorbidity=noted
Documents this conference opened: psa_trend, previous_notes, radiology_report
